WoundWatch™: Monitoring of Venous Ulcers Using a Bioimpedance Measurement Based Method and System

Sponsor
CutoSense Oy (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05805137
Collaborator
University Clinical Centre, Gdansk (Other), Medical University of Gdańsk (Other)
20
1
1
8.9
2.2

Study Details

Study Description

Brief Summary

The purpose of this study is to investigate the functionality of a new type of wound monitoring method and measurement system for monitoring healing of venous ulcers. The system is consisted of a wound dressing with electrodes (eDressing), a bioimpedance measurement device and a mobile phone application.

Condition or Disease Intervention/Treatment Phase
  • Device: WoundWatch wound management system
N/A

Detailed Description

The technical principle of the monitoring method is based on the quasimonopolar bioimpedance measurement. The measurement system consists of a bioimpedance measuring device, a wound dressing with electrodes (eDressing) and a mobile application for use with a mobile phone.

The electrode dressing is placed on top of a wound, in contact with the wound tissue. The other necessary dressing layers (such as absorbent dressings and compression bandages) are placed over the electrode dressing. The aim is to keep the electrode bandage on the wound for seven consecutive days. Other dressings can be changed when necessary. However, the electrode dressing can be removed and replaced whenever due to medical necessity.

During a study subject visit, the bioimpedance measurement is made, the uppermost dressings are opened carefully and it is ensured that the wound condition is as expected. Upon the replacement of the electrode dressing, the wound is photographed and documented. The wound area is measured, and the findings are recorded.

A maximum of 20 subjects (10 to 20 subjects) with venous ulcers will be recruited for the study. Adults with venous ulcer who are applicable for compression therapy treatment and whose wound(s) fit on the area of no larger than 5 x 5 cm and whose wounds are do excrete excessively can be recruited to the study. Previous surgical venous procedure is not an exclusion criteria for enrollment, but surgical procedure can not be performed during the study.

A subject shall visit the clinic 2-3 times a week, according to the doctor's or study nurse's assessment. Wound healing is monitored until the wound re-epithelized (>90% of initial wound surface area) or maximum two months. Thus, there will be a maximum of 24 study visits per subject.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Monitoring of Venous Ulcers Using a Bioimpedance Measurement Based Method and System
Anticipated Study Start Date :
Apr 3, 2023
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Study subject with venous ulcer

The subjects will be monitored using the WoundWatch wound management system two to three study visits per week until the venous ulcer has healed (surface area has decreased at least 90%) or up to two months.

Device: WoundWatch wound management system
eDressing will be applied along with the compression therapy and the standard absorbing dressings. The subjects will be monitored using the WoundWatch wound management system. The subjects will have two to three study visits per week until the venous ulcer has healed (surface area has decreased at least 90%) or up to two months.
Other Names:
  • Bioimpedance measurement of wound healing
  • Outcome Measures

    Primary Outcome Measures

    1. Wound Status Index (WSI) vs. wound surface area [From admission to discharge, up to 8 weeks.]

      Correlation analysis between the WSI and the wound surface area. The WSI is derived from the bioimpedance measurement results.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age at least 18 years

    • The subject has a chronic lower extremity ulcer with a primary etiology of venous insufficiency. The previous venous procedure is not an obstacle to the study

    • Compression therapy can be implemented

    • The wound has a maximum surface area of 5 x 5 cm and can fit in an area of 5 cm x 5 cm. The wound should be located above the ankle, on the skin area where the electrode dressing can be placed properly.

    • The wound is not deep with steep edges or cavity-like

    • The wound is not highly excreting

    • The wound can be expected to heal within two months (area reduced ≥ 90% from baseline)

    • The subject gives consent to the study and commits to following the instructions of the medical staff

    Exclusion Criteria:
    • Clinical wound infection at the time of the study

    • The subject has an intravenous procedure within 2 months

    • Significant arterial circulatory disorder or adherence problem that prevents compression therapy

    • Subject movement 2-3 times a week during the study to the study site is difficult to arrange

    • Diagnosed epoxy resin allergy

    • Any other reasons of potential study subject non-compliance by the opinion of the investigator

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Clinical Centre, Gdańsk Gdańsk Poland

    Sponsors and Collaborators

    • CutoSense Oy
    • University Clinical Centre, Gdansk
    • Medical University of Gdańsk

    Investigators

    • Principal Investigator: Piotr Spychalski, MD, Ph.D., Department of General, Endocrine and Transplant Surgery, Medical University of Gdansk

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    CutoSense Oy
    ClinicalTrials.gov Identifier:
    NCT05805137
    Other Study ID Numbers:
    • WW001
    First Posted:
    Apr 7, 2023
    Last Update Posted:
    Apr 10, 2023
    Last Verified:
    Apr 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by CutoSense Oy
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 10, 2023